Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft‐versus‐host disease following allogeneic hematopoietic stem cell transplantation
- 25 August 2006
- journal article
- clinical trial
- Published by Wiley in American Journal of Hematology
- Vol. 82 (1), 45-52
- https://doi.org/10.1002/ajh.20752
Abstract
Etanercept is a recombinant human soluble tumor necrosis factor (TNF‐α) receptor fusion protein that inhibits TNF‐α, a major mediator in the pathogenesis of graft‐versus‐host disease (GVHD). The purpose of our study was to evaluate the safety and efficacy of etanercept therapy in 21 patients with steroid‐refractory acute GVHD (aGVHD) (n = 13) and chronic GVHD (cGVHD) (n = 8). Etanercept 25 mg was given subcutaneously twice weekly for 4 weeks followed by 25 mg weekly for 4 weeks. At the time of initiation of etanercept, 14 patients had skin, 13 had gastro‐intestinal, 5 had liver, 5 had pulmonary, and 4 had oral involvement. Twelve patients (57%) completed 12 doses of therapy. Overall, 11 of 21 patients (52%) responded to the treatment with etanercept, including 6 patients (46%) with aGVHD [n = 4 complete response (CR), n = 2 partial response (PR)] and 5 patients (62%) with cGVHD (n = 1 CR, n = 4 PR). Clinical responses were most commonly seen in patients with refractory gut aGVHD with 55% of the patients having a CR and 9% having a PR. CMV reactivation occurred in 48% of patients, bacterial infections in 14% of patients, and fungal infections in 19% of patients. Fourteen patients (67%) were alive after a median follow‐up of 429 days (range 71–1007 days) since initiation of etanercept. Seven patients died, 3 of infections, 2 of refractory aGVHD, and 2 of disease progression. In conclusion, our preliminary data indicate that etanercept is well tolerated and can induce a high response rate in patients with steroid‐refractory aGVHD and cGVHD, particularly in the setting of GI involvement. Am. J. Hematol., 2006.Keywords
This publication has 26 references indexed in Scilit:
- Prospective Monitoring of Tumor Necrosis Factor α and Interferon γ to Predict the Onset of Acute and Chronic Graft-versus-Host Disease after Allogeneic Stem Cell TransplantationTransplantation and Cellular Therapy, 2005
- Pilot Trial on the Use of Etanercept and Methylprednisolone as Primary Treatment for Acute Graft-versus-Host DiseaseTransplantation and Cellular Therapy, 2005
- Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanerceptBone Marrow Transplantation, 2005
- Clinical responses following nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma are associated with expansion of CD8+ IFN-γ-producing T cellsBone Marrow Transplantation, 2004
- Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trialBlood, 2002
- Murine graft-versus-host disease induced using interferon-gamma-deficient grafts features antibodies to double-stranded DNA, T helper 2-type cytokines and hypereosinophiliaImmunology, 2002
- Chronic graft-versus-host disease: clinical manifestation and therapyBone Marrow Transplantation, 2001
- Etanercept in graft-versus-host diseaseBone Marrow Transplantation, 2000
- Graft-versus-Host DiseaseNew England Journal of Medicine, 1991
- CLINICAL MANIFESTATIONS OF GRAFT-VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL-A-MATCHED SIBLING DONOR,STransplantation, 1974